Pembrolizumab in the first-line treatment of advanced head and neck cancer

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. published Online First: 2018/09/13
   PubMed Web of Science ®Google Scholar
• Marur S, D’Souza G, Westra WH, et al. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol. 2010;11(8):781–789. [published Online First: 2010/05/11].
   PubMed Web of Science ®Google Scholar
• Sturgis EM, Ang KK. The epidemic of HPV-associated oropharyngeal cancer is here: is it time to change our treatment paradigms? J Natl Compr Canc Netw. 2011;9(6):665–673. published Online First: 2011/06/04
   PubMed Web of Science ®Google Scholar
• Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363(1):24–35.
   PubMed Web of Science ®Google Scholar
• O’Sullivan B, Huang SH, Su J, et al. Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study. Lancet Oncol. 2016;17(4):440–451.
   PubMed Web of Science ®Google Scholar
• Pignon JP, le Maître A, Maillard E, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009;92(1):4–14. published Online First: 2009/05/19
   PubMed Web of Science ®Google Scholar
• Chang JH, Wu CC, Yuan KS, et al. Locoregionally recurrent head and neck squamous cell carcinoma: incidence, survival, prognostic factors, and treatment outcomes. Oncotarget. 2017;8(33):55600–55612. [published Online First: 2017/09/15]
   PubMedGoogle Scholar
• Leon X, Hitt R, Constenla M, et al. A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy. Clin Oncol (R Coll Radiol). 2005;17(6):418–424. [published Online First: 2005/09/10].
   PubMed Web of Science ®Google Scholar
• •Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359(11):1116–1127. published Online First: 2008/09/12
   PubMed Web of Science ®Google Scholar
• Stewart JS, Cohen EE, Licitra L, et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. J Clin Oncol. 2009;27(11):1864–1871. published Online First: 2009/03/18
   PubMed Web of Science ®Google Scholar
• Specenier P, Rasschaert M, Vroman P, et al. Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Am J Clin Oncol. 2011;34(5):472–477. [published Online First: 2010/10/13].
   PubMed Web of Science ®Google Scholar
• Chung CH, Parker JS, Karaca G, et al. Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell. 2004;5(5):489–500.
   PubMed Web of Science ®Google Scholar
• Walter V, Yin X, Wilkerson MD, et al. Molecular subtypes in head and neck cancer exhibit distinct patterns of chromosomal gain and loss of canonical cancer genes. PLoS One. 2013;8(2):e56823. [published Online First: 2013/03/02].
   PubMed Web of Science ®Google Scholar
• Lawrence MS, Sougnez C, Lichtenstein L, et al. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015;517(7536):576–582.
   PubMed Web of Science ®Google Scholar
• Mandal R, Şenbabaoğlu Y, Desrichard A, et al. The head and neck cancer immune landscape and its immunotherapeutic implications. JCI Insight. 2016;1(17):e89829. [published Online First: 2016/10/26].
   PubMed Web of Science ®Google Scholar
• •Seiwert TY, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016;17(7):956–965. [published Online First: 2016/06/02].
   PubMed Web of Science ®Google Scholar
• ••Ferris RL, Blumenschein G Jr., Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856–1867. [published Online First: 2016/10/11].
   PubMed Web of Science ®Google Scholar
• ••Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394(10212):1915–1928. [published Online First: 2019/11/05].
   PubMed Web of Science ®Google Scholar
• •• Cohen EEW, Soulieres D, Le TC, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet. 2019;393(10167):156–167. [published Online First: 2018/12/05].
   PubMed Web of Science ®Google Scholar
• •Yang WF, Wong MCM, Thomson PJ, et al. The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: a systematic review and meta-analysis. Oral Oncol. 2018;86:81–90. [published Online First: 2018/11/10].
   PubMed Web of Science ®Google Scholar
• Pai SI, Faivre S, Licitra L, et al. Comparative analysis of the phase III clinical trials of anti-PD1 monotherapy in head and neck squamous cell carcinoma patients (CheckMate 141 and KEYNOTE 040). J Immunother Cancer. 2019;7(1):96. [published Online First: 2019/04/05].
   PubMedGoogle Scholar
• Zandberg DP, Strome SE. The role of the PD-L1: PD-1pathway in squamous cell carcinoma of the head and neck. Oral Oncol. 2014;50(7):627–632. [published Online First: 2014/05/14].
   PubMed Web of Science ®Google Scholar
• Qiao XW, Jiang J, Pang X, et al. The evolving Landscape of PD-1/PD-L1 pathway in head and neck cancer. Front Immunol. 2020;11:1721. [published Online First: 2020/10/20].
   PubMed Web of Science ®Google Scholar
• Ishida Y, Agata Y, Shibahara K, et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. Embo J. 1992;11(11):3887–3895. [published Online First: 1992/11/01].
   PubMed Web of Science ®Google Scholar
• Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568–571. [published Online First: 2014/11/28].
   PubMed Web of Science ®Google Scholar
• Concha-Benavente F, Srivastava RM, Trivedi S, et al. Identification of the cell-intrinsic and -extrinsic pathways downstream of EGFR and IFNγ that induce PD-L1 expression in head and neck cancer. Cancer Res. 2016;76(5):1031–1043. [published Online First: 2015/12/18].
   PubMed Web of Science ®Google Scholar
• Keytruda, MERCK. [ Available from: https://www.keytruda.com].
   Google Scholar
• •Chow LQM, Haddad R, Gupta S, et al. Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the Phase Ib KEYNOTE-012 expansion cohort. J Clin Oncol. 2016;34(32):3838–3845. [published Online First: 2016/09/21].
   PubMed Web of Science ®Google Scholar
• •Mehra R, TY S, Gupta S, et al. Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. Br J Cancer. 2018;119(2):153–159. [published Online First: 2018/06/30].
   PubMed Web of Science ®Google Scholar
• •Bauml J, Seiwert TY, Pfister DG, et al. Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: results from a single-arm, Phase II study. J Clin Oncol. 2017;35(14):1542–1549. [published Online First: 2017/03/23].
   PubMed Web of Science ®Google Scholar
• Saâda-Bouzid E, Defaucheux C, Karabajakian A, et al. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol. 2017;28(7):1605–1611. [published Online First: 2017/04/19].
   PubMed Web of Science ®Google Scholar
• Karabajakian A, Garrivier T, Crozes C, et al. Hyperprogression and impact of tumor growth kinetics after PD1/PDL1 inhibition in head and neck squamous cell carcinoma. Oncotarget. 2020;11(18):1618–1628. [published Online First: 2020/05/15].
   PubMedGoogle Scholar
• Economopoulou P, Kotsantis I, Psyrri A. The promise of immunotherapy in head and neck squamous cell carcinoma: combinatorial immunotherapy approaches. ESMO Open. 2016;1(6):e000122. [published Online First: 2017/08/30].
   PubMed Web of Science ®Google Scholar
• • European Medicines Agency. Public Assessment Report, Keytruda 2019 [ Available from: https://www.ema.europa.eu/en/documents/variationreport/keytruda-h-c-3820-ii-0065-epar-assessment-report-variation_en.pdf2021.
   Google Scholar
• Zandberg DP, Algazi AP, Jimeno A, et al. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy. Eur J Cancer. 2019;107:142–152. [published Online First: 2018/12/24].
   PubMed Web of Science ®Google Scholar
• Siu LL, Even C, Mesía R, et al. Safety and efficacy of durvalumab with or without tremelimumab in patients with PD-L1–Low/Negative recurrent or metastatic HNSCC: the Phase 2 CONDOR randomized clinical trial. JAMA Oncol. 2019;5(2):195–203.
   PubMed Web of Science ®Google Scholar
• Ferris RL, Haddad R, Even C, et al. Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study. Ann Oncol. 2020;31(7):942–950. [published Online First: 2020/04/16].
   PubMed Web of Science ®Google Scholar
• Seiwert TY, Weiss J, Baxi SS, et al. A phase 3, randomized, open-label study of first-line durvalumab (MEDI4736) ± tremelimumab versus standard of care (SoC; EXTREME regimen) in recurrent/metastatic (R/M) SCCHN: KESTREL. J Clin Oncol. 2016;34(15_suppl): TPS6101–TPS01.
   PubMed Web of Science ®Google Scholar
• AstraZeneca. Update on KESTREL Phase III trial of Imfinzi with or without tremelimumab in the 1st-line treatment of recurrent or metastatic head and neck cancer. News release. 2021 [ Available from: [cited 2021 Jun 21]. https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2021/update-on-kestrel-phase-iii-trial-for-imfinzi.html
   Google Scholar
• Hanna GJ, Lizotte P, Cavanaugh M, et al. Frameshift events predict anti–PD-1/L1 response in head and neck cancer. JCI Insight. 2018;3(4):4.
   Web of Science ®Google Scholar
• Vassilakopoulou M, Avgeris M, Velcheti V, et al. Evaluation of PD-L1 expression and associated tumor-infiltrating lymphocytes in laryngeal squamous cell carcinoma. Clin Cancer Res. 2016;22(3):704–713.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas N. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015;517(7536): 576–582.
   PubMed Web of Science ®Google Scholar
• Locati LD, Serafini MS, Iannò MF, et al. Mining of self-organizing map gene-expression portraits reveals prognostic stratification of HPV-positive head and neck squamous cell carcinoma. Cancers (Basel). 2019;11(8):1057. [published Online First: 2019/07/31].
   Web of Science ®Google Scholar
• Kato Y, Tabata K, Hori Y, et al. Abstract A92: effects of lenvatinib on tumor-associated macrophages enhance antitumor activity of PD-1 signal inhibitors: AACR, 2015.
   Google Scholar
• Kato Y, Bao X, Macgrath S, et al. Lenvatinib mesilate (LEN) enhanced antitumor activity of a PD-1 blockade agent by potentiating Th1 immune response. Ann Oncol. 2016;27:vi1.
   Web of Science ®Google Scholar
• Taylor MH, Rasco DW, Brose MS, et al. A phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with squamous cell carcinoma of the head and neck. J Clin Oncol. 2018;36(15_suppl):6016.
   Google Scholar
• Taylor MH, Lee CH, Makker V, et al. Phase IB/II trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors. J Clin Oncol. 2020;38(11):1154–1163. [published Online First: 2020/01/22].
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol. 2007;25(16):2171–2177. [published Online First: 2007/06/01].
   PubMed Web of Science ®Google Scholar
• Baselga J, Trigo JM, Bourhis J, et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol. 2005;23(24):5568–5577. [published Online First: 2005/07/13].
   PubMed Web of Science ®Google Scholar
• Herbst RS, Arquette M, Shin DM, et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol. 2005;23(24):5578–5587. [published Online First: 2005/07/13].
   PubMed Web of Science ®Google Scholar
• Sacco AG, Chen R, Worden FP, et al. Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial. Lancet Oncol. 2021;22(6):883–892. [published Online First: 2021/05/15].
   PubMed Web of Science ®Google Scholar
• Manieri NA, Chiang EY, Grogan JL. TIGIT: a key inhibitor of the cancer immunity cycle. Trends Immunol. 2017;38(1):20–28.
   PubMed Web of Science ®Google Scholar
• Wu L, Mao L, Liu J-F, et al. Blockade of TIGIT/CD155 signaling reverses T-cell exhaustion and enhances antitumor capability in head and neck squamous cell carcinoma. Cancer Immunol Res. 2019;7(10):1700–1713.
   PubMed Web of Science ®Google Scholar
• Mao L, Xiao Y, Yang Q-C, et al. TIGIT/CD155 blockade enhances anti-PD-L1 therapy in head and neck squamous cell carcinoma by targeting myeloid-derived suppressor cells. Oral Oncol. 2021;121:105472.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Abreu D, Johnson ML, Hussein MA, et al. Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE). J Clin Oncol. 2020;38(15_suppl):9503.
   Web of Science ®Google Scholar
• Cohen RB, Bauman JR, Salas S, et al. Combination of monalizumab and cetuximab in recurrent or metastatic head and neck cancer patients previously treated with platinum-based chemotherapy and PD-(L)1 inhibitors. J Clin Oncol. 2020;38(15_suppl):6516.
   Google Scholar
• Massarelli E, William W, Johnson F, et al. Combining immune checkpoint blockade and tumor-specific vaccine for patients with incurable human papillomavirus 16-related cancer: a Phase 2 clinical Trial. JAMA Oncol. 2019;5(1):67–73. [published Online First: 2018/09/30].
   PubMed Web of Science ®Google Scholar
• Aggarwal C, Saba NF, Algazi AP, et al. 916MO - Safety and efficacy of MEDI0457 plus durvalumab in patients (pts) with human papillomavirus-associated recurrent/metastatic head and neck squamous cell carcinoma (HPV+ R/M HNSCC). Ann Oncol. 2020;31:599–S628.
   PubMed Web of Science ®Google Scholar
• Gomes-da-Silva LC, Kepp O, Kroemer G. Regulatory approval of photoimmunotherapy: photodynamic therapy that induces immunogenic cell death. Oncoimmunology. 2020;9(1):1841393. [published Online First: 2020/11/13].
   PubMed Web of Science ®Google Scholar
• Cognetti DM, Johnson JM, Curry JM, et al. Results of a phase 2a, multicenter, open-label, study of RM-1929 photoimmunotherapy (PIT) in patients with locoregional, recurrent head and neck squamous cell carcinoma (rHNSCC). J Clin Oncol. 2019;37(15_suppl):6014.
   Web of Science ®Google Scholar
• Nagarsheth NB, Norberg SM, Sinkoe AL, et al. TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers. Nat Med. 2021;27(3):419–425. [published Online First: 2021/02/10].
   PubMed Web of Science ®Google Scholar
• Doran SL, Stevanović S, Adhikary S, et al. T-Cell receptor gene therapy for human papillomavirus-associated epithelial cancers: a first-in-human, Phase I/II study. J Clin Oncol. 2019;37(30):2759–2768. [published Online First: 2019/08/14].
   PubMed Web of Science ®Google Scholar
• (FDA) FaDA. FDA approves pembrolizumab for first-line treatment of head and neck squamous cell carcinoma. [ accessed Jun 2021. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-first-line-treatment-head-and-neck-squamous-cell-carcinoma.
   Google Scholar
• Agency EM. Keytruda [cited May 2021]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda.
   Google Scholar
• Gibson MK, Li Y, Murphy B, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2005;23(15):3562–3567. published Online First: 2005/05/24
   PubMed Web of Science ®Google Scholar
• Guigay J, Fayette J, Mesia R, et al. TPExtreme randomized trial: TPEx versus extreme regimen in 1st line recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). J Clin Oncol. 2019;37(15_suppl):6002.
   Google Scholar
• Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non–small-cell lung cancer. N Engl J Med. 2018;379(21):2040–2051.
   PubMed Web of Science ®Google Scholar